Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech Eyes $450m Funding And Public Listing With SPAC Merger

Proposed Combination Would Have Initial Enterprise Value Of Around $2.25bn

Executive Summary

Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.

You may also be interested in...



Who’s Hired? Teva Gets New Leadership In Canada

Teva has appointed a new general manager in Canada following the departure of Christine Poulin to Covis Pharma. At the same time, Amneal’s associate general counsel, Meredith Cook, has taken up a role at ANI Pharmaceuticals, while Alvotech has appointed several new directors to its board as part of its transition to being a publicly-listed company.

Icelandic Exchange Approves Alvotech As Its Shares Trade In NY

Alvotech is celebrating an “historic milestone” as it became a publicly listed company in New York, with its shares set to also trade in its domestic Iceland next week.

Alvotech On The Verge Of New Chapter As SPAC Merger Is Approved

Alvotech will cease to be a privately listed company next week, with its merger with special purpose acquisition company Oaktree Acquisition Corp. II set to close “on or about 15 June.”

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel